A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)

Inclusion Criteria: * The adult patient (≥18 years of age) has given written informed consent to participate in the study. * The patient has been prescribed for ONIVYDE treatment according to the ONIVYDE China mainland SmPC. * Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas. * Documented metastatic disease. * Patient deemed not eligible or failed previous treatment with gemcitabine or gemcitabine containing therapy. Exclusion Criteria: * Patients who have experienced a severe hypersensitivity reaction to ONIVYDE or Irinotecan HCL. * Patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation or confirmed diagnostic of interstitial lung disease. * Pregnant or nursing (lactating) women. * Patients without highly effective methods of contraception during study treatment until 3 months after the last dose of the study drug, Specially,7 months for women of childbearing potential and 4 months for male with partners of childbearing potential after the last dose of the study drug. * Other additional exclusions may be applied by the investigator according to the contexts, in order to ensure that the study population will be non-interventional but representative of all eligible subjects.